ANGLE’s Parsortix system has
the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.” Andrew Newland Chief Executive
The Parsortix system is simple, effective and affordable
Capture circulating tumor cells that aren’t being caught by antibody (often EpCAM) based systems – this includes the capture of mesenchymal cells and CTC clusters
High capture efficiency and purity of CTCs
Easy access to the CTCs to feed a wide range of downstream analysis – including protein expression, DNA/ RNA analysis and single cell picking/ analysis
Plasma for ctDNA analysis can be removed prior to processing the cellular component of a blood sample – hence ctDNA and CTCs from a single sample.
Cells recovered from the Parsortix system are viable
Simple operation with minimal user intervention required.